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Aims Hyperaldosteronism is associated with vascular injury and increased cardiovascular events. Bone marrow-derived
endothelial progenitor cells (EPCs) play an important role in endothelial repair and vascular homeostasis. We hypoth-
esized that hyperaldosteronism impairs EPC function and vascularization capacity in mice and humans.
Methods
and results
We characterized the effects of aldosterone and mineralocorticoid receptor (MR) blockade on EPC number and
function as well as vascularization capacity and endothelial function. Treatment of human EPC with aldosterone
induced translocation of the MR and impaired multiple cellular functions of EPC, such as differentiation, migration,
and proliferation in vitro. Impaired EPC function was rescued by pharmacological blockade or genetic ablation of
the MR. Aldosterone protein kinase A (PKA) dependently increased reactive oxygen species formation in EPC.
Aldosterone infusion in mice impaired EPC function, EPC homing to vascular structures and vascularization capacity
in a MR-dependent but blood pressure-independent manner. Endothelial progenitor cells from patients with primary
hyperaldosteronism compared with controls of similar age displayed reduced migratory potential. Impaired EPC func-
tion was associated with endothelial dysfunction. MR blockade in patients with hyperaldosteronism improved EPC
function and arterial stiffness.
Conclusion Endothelial progenitor cells express a MR that mediates functional impairment by PKA-dependent increase of reac-
tive oxygen species. Normalization of EPC function may represent a novel mechanism contributing to the beneﬁcial
effects of MR blockade in cardiovascular disease prevention and treatment.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Endothelial progenitor cells (EPCs) are a heterogeneous cell popu-
lation that circulate in the blood and contribute to the formation of
new blood vessels, endothelial repair, and vascular homeostasis by
direct and indirect mechanisms.
1–4 Impairment of EPCs is related
to endothelial dysfunction,
5,6 coronary artery disease,
7,8 and
adverse clinical outcome.
9,10 Endothelial progenitor cells express
a variety of receptors that mediate functional effects of endogen-
ous hormones and growth factors by changing the intracellular
balance of reactive oxygen species and endothelial nitric oxide
synthase-derived NO.
3,6,11–13
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European Heart Journal (2011) 32, 1275–1286
doi:10.1093/eurheartj/ehq254Activation of the renin–angiotensin–aldosterone system plays an
important role in the pathogenesis of atherosclerosis and its compli-
cations,suchasvasculardysfunctionandcoronaryarterydisease.
14,15
In contrast to the classical notion that mineralocorticoids were only
involved in body electrolyte and water homeostasis mediated by
the kidney, aldosterone exerts important (patho)physiological
effectsonthecardiovascularsystem.
14,16–19Aldosteronetargetscar-
diomyocytes,
17,20cardiacﬁbroblasts,
21and endothelial cells
18leading
to cardiac hypertrophy, ﬁbrosis, and vascular injury. Upon binding to
the mineralocorticoid receptor (MR), aldosterone increases vascular
endothelial and vascular smooth muscle cell superoxide anion pro-
duction.
15,18,22,23 High levels of aldosterone impair vascular function
and predictmortality riskofpatientswith acute myocardialinfarction
orheartfailure.
16,24Patientswithprimaryhyperaldosteronism(PHA)
display a higher incidence of myocardial infarction and stroke.
25
Mineralocorticoid receptor antagonism in patients with heart
failure ameliorates endothelial function
26–28 and large clinical trials
have shown MR blockade to decrease mortality in cardiovascular
disease.
29,30
The effects of aldosterone on EPC function and vascularization
capacity in mice and humans are unclear. We therefore studied MR
expression in various subtypes of EPCs. In vitro and in vivo studies
were performed to investigate the effects of aldosterone on EPC
function, endothelial function, and overall vascularization capacity.
Finally, we tested whether MR antagonism would improve EPCs
and markers of endothelial function in mice infused with aldoster-
one and patients with PHA.
Methods
Isolation, characterization, and culture of
human and mouse endothelial progenitor cell
This was done essentially as described.
11,31,32 A considerable number
of different EPC subtypes exist and the nomenclature is rather hetero-
geneous (see
33 for review). We therefore here describe the different
subtypes of cells we used in our studies and also mention this in the
Results section; in brief, we used the following cells for our analyses,
which have been extensively described and characterized in the litera-
ture: monocytic EPCs,
11,34 CD34
+/KDR
+ cells (human study),
35 sca1/
ﬂk1 cells (mouse study),
11 early outgrowth (colony-forming units, CFU
assays or ‘Hill’ colonies)
31 and late-outgrowth EPCs.
32 Note, that alter-
natively to the term ‘monocytic EPC’ also ‘early EPC’, ‘angiogenic pro-
genitor cells’, or ‘circulating angiogenic cells’
33 are used in the
literature. All of the employed EPC subtypes expressed the MR (see
Supplementary material online, Figure S1 and data not shown). For
morphology and characteristics of late-outgrowth EPCs, see Sup-
plementary material online, Figure S2. As cell culture media we used
endothelial basal medium (EBM-2, Lonza, Germany) supplemented
with EGM-2 BulletKit (for aldosterone experiments without addition
of hydrocortisone to avoid cross-talk with the MR).
Mineralocorticoid receptor expression
analysis and cellular distribution
Gene expression of the MR (NR3C2) was detected by RT-PCR as
described
36 and using 5′-ATCACGATCGGCTAGAGACC-3′ and
5′-CCCATAATGGCATCCTGAAG-3′ as oligonucleotides. To deter-
mine protein expression, cell lysates (50 mg) from cultured EPCs or
human umbilical vein endothelial cells (positive control
37) were
separated on 12% SDS-polyacrylamide gels. Primary antibodies
included anti-MR (ab2774) and anti-GAPDH (ab8245) (both Abcam,
Cambridge, UK). Mineralocorticoid receptor expression was addition-
ally determined by immunohistochemistry after addition of an
anti-MR-antibody (ab2774, Abcam) overnight. Thereafter cells were
washed and a rhodamine-labelled mouse IgG antibody was added for
2 h. Cellular distribution of the MR was investigated before and after
addition of aldosterone (1 mg) for 2 h.
Determination of endothelial progenitor cell
number and function
A variety of assays were used to determine the effects of aldosterone
and MR blockade on EPC number, differentiation, and function:
This included an EPC adhesion-related cell culture assay for the
identiﬁcation of monocytic (early) EPCs, the detection of CD34
+/
VEGFR-2
+ cells (human study) or sca-1
+/ﬂk-1
+ cells (mouse study),
DiI-acLDL uptake, Ulex europeus-1 (UEA-1) binding, the determi-
nation of endothelial CFU, and analysis of the migratory capacity of
EPCs towards an vascular endothelial growth factor (VEGF)/stromal-
derived factor-1 (SDF-1) gradient. These assays were essentially
done as described.
11,12,31
Small interference RNA-mediated
knockdown of the mineralocorticoid
receptor
Endothelial progenitor cells were transfected with siRNA against
NR3C2 or scrambled controls using the StealthTM Select RNAi Kit
(Invitrogen, Germany; oligonucleotide concentration 150 nM, 48 h).
FITC-labelled scrambled siRNA (control-FITC block-it ﬂuorescent
Oligo #2013, Invitrogen, Germany) was used as a transfection
control. Transfection rate was .90% (data not shown). Forty-eight
hours after transfection, NR3C2 expression was monitored by
RT-PCR and western blot analysis (see above-mentioned section).
Measurement of reactive oxygen species
Intracellular reactive oxygen species (ROS) was determined using dihy-
droethidium (DHE) as described.
12 After 20 min of incubation with
DHE (2.5 mM) at 378C and 5% CO2 in a humidiﬁed atmosphere,
EPCs were evaluated using ﬂuorescence microscopy. Signal intensity
of cells and background was determined in at least four randomly
chosen regions.
Aldosterone level
Plasma aldosterone levels were measured by commercially available
radioimmunoassays (mice: DiaSorin GmbH, Dietzenbach, Germany;
humans: DPC Biermann, Bad Nauheim, Germany).
Mouse in vivo studies
The study conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publi-
cation No. 85-23, revised 1996). To test whether hyperaldosteronism
would alter EPC biology, neovascularization capacity and endothelial
function in vivo, we implanted osmotic mini-pumps (#1002, Alzet) to
continuously infuse aldosterone (50 mg/kg/d) or vehicle into male
mice (8 weeks of age, Harlan-Winkelmann, Germany). A subgroup
of aldosterone-infused animals was co-treated with the MR antagonist
eplerenone (100 mg/kg/d by oral gavage), the beta-blocker metoprolol
(10 mg/kg/d by i.p. injection) or placebo. Matrigel plugs were implanted
into a further subgroup of mice, which after 10 days received
T. Thum et al. 1276aldosterone- or placebo infusion for 3 days followed by retroorbitally
injection of 1 × 10
6 DiI-acLDL-labelled EPCs, which expressed the MR
or in which the MR has been silenced by siRNA. Twenty-four hours
later, the matrigel plugs were removed and numbers of EPCs within
the matrigel plug were counted. Dosages for aldosterone infusion,
eplerenone, and beta-blocker treatment were estimated based on pre-
vious studies.
18,38,39 Blood pressure of animals was determined using
established tail-cuff measurements (Fo ¨hr Medical Instruments,
Seeheim, Germany).
Determination of endothelial function in
mice and humans
Fourteen days after continuous aldosterone or placebo infusion to
mice, the descending aorta was dissected and cleaned of connective
tissue. Three millimetres of aortic ring segments were studied in
organ chambers (Fo ¨hr Medical Instruments, Seeheim, Germany) for
isometric force measurements as described.
40 Vessels were precon-
stricted with prostaglandine F2a to comparable constriction levels,
and the relevant response to cumulative doses of acetylcholine and
2-(N,N-diethylamino)-diazenolate-2-oxide (DEA-NONOate) (both
1 pmol/l to 10 mmol/l) was assessed.
Endothelial function and arterial stiffness in patients with PHA and
controls of the same age were determined by an established peripheral
arterial tonometry method based on a plethysmographic device
(EndoPAT2000, Itamar-Medical, Israel).
41
Vascularization assays
Matrigel plug assay
Seven days after implantation of osmotic minipumps we injected Matri-
gel (400 ml, Becton Dickinson, #354248, supplemented with 600 ng/
mL basic FGF and 300 ng/mL VEGF). After additional 7 days matrigel
plugs were explanted, shock frozen in TissueTec, sliced, stained with
a mouse CD31 antibody (PECAM-1, #MCA2388, Serotec, dilution
1:50) overnight and subsequently stained with a biotinylated antimouse
antibody and Texas Red Avidin DCS (Vector #A2006) and investigated
by ﬂuorescence microscopy. Nuclei were counterstained by Hoechst
33342 (Molecular probes, dilution 1:500). Vascularization was calcu-
lated by determination of the amount of invading capillaries and
measurement of haemoglobin content of the explanted Matrigel plug
by standard ELISA (Mouse haemoglobin ELISA, E-90HM, Dunn Labor-
technik, Asbach, Germany).
Aortic sprouting assay
In a subset of experiments, the transthoracic aorta was removed after
infusion of aldosterone or placebo (PBS) for 14 days, sliced into 1 mm
rings, placed in matrigel and cultured in EBM2 cell culture media (with
supplements; LONZA, Switzerland) for 5 days. Then the amount of
sprouting outgrowths per aortic ring was counted as a further
marker of vascularization capacity as described.
42
Clinical trial
Approval from the ethical committee of the University of Wu ¨rzburgwas
obtained, as was informed written consent from patients and controls.
WeinvestigatedEPCnumberandfunction,aswellasendothelialfunction
in patients admitted to the Division of Endocrinology (University of
Wurzburg, Germany) because of suspected PHA. Based on an increase
in the aldosterone/renin ratio (.50), pathological saline infusion test,
imagingtestssuchashigh-resolutioncomputedtomographyscanormag-
netic resonance imaging and/or adrenal vein sampling tests, we identiﬁed
10patientswithanaldosterone-producingadenomaandthusPHA.Base-
line characteristics of patients and controls are shown in Table 1.A
subgroup of patients with PHA was treated with spironolactone
(75–100 mg/day) for 4–6 weeks. Changes of EPC number and function,
as well as endothelial function were determined before and after
mineralocorticoid receptor blockade in this subgroup.
Statistical analysis
Data are presented as mean and SEM unless otherwise stated. Statisti-
cal analysis was performed using the StatView (SAS Institute) package.
For statistical comparison of two groups, we employed paired or
unpaired, two-tailed Student’s t-test as appropriate; for the compari-
son of three or more groups, we used ANOVA followed by post-tests.
In the case of the clinical studies there was no normal distribution of
tested parameters within the patients or controls and thus non-
parametric tests were used. We used the Mann–Whitney test for
comparison of parameters between two groups and the Wilcoxon
signed rank test when paired samples were analysed. Differences
were considered signiﬁcant when P ≤ 0.05.
Results
Expression and functional importance of
mineralocorticoid receptor activation for
endothelial progenitor cells
Monocytic (early) EPCs expressed the MR (NR3C2) both at the
gene (Figure 1A) and protein levels (Figure 1B). In addition, the
MR was expressed in all employed types of EPC (Supplementary
material, Figures S1 and S2). In untreated EPC the MR was detect-
able throughout the cell, but upon stimulation with aldosterone
mainly translocated to the peri- and intranuclear region suggesting
activation of the receptor (Figure 1C). The functional effects of MR
................................................................................
................................................................................
Table 1 Characterization of controls and patients
with primary hyperaldosteronism
Controls
(n 5 13)
Primary
hyperaldosteronism
(n 5 10)
P
Age (years) 44.8+3.0 50.6+3.0 NS
Gender, M/F 9/4 8/2 NS
a
Hypertension 3/13 10/10 ,0.001
a
CAD 3/13 3/10 NS
a
Diabetes 2/13 2/10 NS
a
Medication
ACE/ARB 3/13 8/10 ,0.01
a
Beta blocker 3/13 8/10 ,0.01
a
Calcium
antagonist
1/13 7/10 ,0.01
a
Statin 3/13 3/10 NS
a
ASA 3/13 3/10 NS
a
Diuretics 2/13 3/10 NS
a
Metformin 1/13 2/10 NS
a
Values were expressed as mean+SEM where appropriate. ACE, angiotensin
converting enzyme; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid,
CAD, coronary artery disease; F, female; M, male.
ax
2 analysis.
Aldosterone impairs EPC function and vascularization 1277stimulation on EPC biology were then tested in a series of in vitro
assays. Aldosterone treatment impaired formation of endothelial
CFU and of UEA-1
+/dil-acLDL
+ cells from cultured peripheral
blood mononuclear cells, indicating inhibition of EPC differen-
tiation and functional impairment (Figure 2A and B). Migratory
capacity of monocytic (early) EPCs towards a SDF-1/VEGF gradi-
ent was dose dependently attenuated by aldosterone but not
hydrocortisone (see Figure 2C and Supplementary material
online, Figure S3). Likewise, aldosterone inhibited migration of
human late-outgrowth EPCs (see Supplementary material online,
Figure S2). Expression of the SDF-1 receptors CXCR4 and
CXCR7 was unaffected by aldosterone treatment (data not
shown). Selective pharmacological inhibition of the MR by eplere-
none (Figure 2A–D) or genetic ablation of the MR by siRNA abol-
ished aldosterone-mediated functional impairment of EPCs (see
Figure 2D and Supplementary material online, Figure S2). As EPCs
may additionally contribute to angiogenesis by a paracrine mode
of action,
43 we screened for altered production of different
angiogenic cytokines and growth factors (VEGF), stem cell
factor, hepatocyte growth factor, platelet-derived growth factor
bb, ﬁbroblast growth factor 2, granulocyte macrophage colony-sti-
mulating factor, IL-2, IL-4, IL-6, monocyte chemotactic protein-1,
chemokine (C-C motif) ligand 5 (CCF5 or RANTES) and
tumour necrosis factor alpha (TNF-alpha), but did not detect
signiﬁcant differences (data not shown). We thus conclude that
aldosterone directly impairs EPC function without major effects
on paracrine activity.
Aldosterone increases oxidative stress in
monocytic (early) endothelial progenitor
cells in a protein kinase A-dependent
manner
Endothelial progenitor cell function is impaired by ROS.
6,12,31 We
tested whether aldosterone would alter ROS formation in mono-
cytic (early) and late-outgrowth EPC. Treatment of EPC with
aldosterone led to an up to four-fold increase in intracellular
ROS production, which was blocked by pre-treatment of EPC
with eplerenone or siRNA-mediated silencing of the MR (see
Figure 3A and B and Supplementary material online, Figure S2).
The protein kinases (PK) A and C are involved in endothelial
ROS production. Inhibition of aldosterone PKA alleviated
aldosterone-mediated ROS production of EPC, whereas PKC inhi-
bition had only minor effects (Figure 3B). Aldosterone-stimulated
ROS formation impaired the migratory potential of EPC, which
could be completely normalized by concomitant PKA, but not
PKC inhibition (Figure 3C).
Aldosterone impairs monocytic (early)
endothelial progenitor cell function,
vascularization capacity, and endothelial
function in vivo
To determine whether the in vitro ﬁndings of aldosterone-mediated
EPC dysfunction were operative in vivo, we implanted osmotic
Figure 1 Expression of mineralocorticoid receptor (NR3C2) in endothelial progenitor cells (EPCs). (A) Gene expression, (B) protein
expression of NR3C2 (mineralocorticoid receptor) and GAPDH in human monocytic EPCs. Human umbilical vein endothelial cells
(control) served as positive controls for NR3C2 expression.
37 (C) Fluorescence microscopic detection of NR3C2 expression in untreated
(left) and aldosterone-treated (1 mg, 2 h) human EPCs. 4’,6-diamidino-2-phenylindole (DAPI) was used to visualize nuclei. Exemplary pic-
tures/blots from at least three independent experiments are shown.
T. Thum et al. 1278minipumps in the wild-type mice to infuse either aldosterone
(50 mg/kg/day) or vehicle for 14 days. Aldosterone infusion
increased blood pressure, which was attenuated by concomitant
eplerenone treatment (Figure 4A and B). We found no changes
in the number of circulating sca-1
+/ﬂk-1
+ EPC (control: 0.45+
0.06% sca-1
+/ﬂk-1
+ cells; aldosterone infusion: 0.40+0.06%
sca-1
+/ﬂk-1
+ cells; P ¼ n.s.), but an increase of intracellular ROS
levels in response to aldosterone infusion (Figure 4C). This resulted
in impaired monocytic (early) EPC differentiation and function
based on migratory activity studies and could be completely pre-
vented by co-treatment with the selective MR blocker eplerenone
(Figure 4D and E). In control animals, eplerenone had no signiﬁcant
effects on cellular ROS formation or migratory capacity, but
improved EPC differentiation (Figure 4C–E). Hyperaldosteronism
prevented homing of monocytic (early) EPCs to implanted matrigel
plugs, which was completely normalized if the MR had been
silenced by a siRNA approach (Figure 4F). Note that infused EPC
both integrated and/or ﬁrmly adhered to preformed capillaries
in matrigel plugs (Figure 4G). In a further study we wanted
to exclude signiﬁcant effects of aldosterone-induced blood
pressure increase per se on number and function of circulating
sca-1
+/ﬂk-1
+ EPC. Here, we co-treated the aldosterone-infused
mice additionally with the beta-blocker metoprolol, which
prevented blood pressure increase (see Supplementary material
Figure 2 Mineralocorticoid receptor-dependent effects of aldosterone on endothelial progenitor cell (EPC) function. Effects of aldosterone
(Aldo, 1–100 ng/mL) and selective blockade by concomitant eplerenone treatment (Epl, 10 mM) on EPC-colony forming unit capacity (A),
monocytic (early) EPC differentiation measured by diI-acLDL uptake and UEA-1 staining (B) and EPC migratory capacity using modiﬁed
Boyden chambers (C). (D) SiRNA-mediated knockdown of mineralocorticoid receptor (NR3C2; left) alleviated the detrimental effects of aldos-
terone on EPC migration in a modiﬁed Boyden chamber assay (right). Data are mean and SEM. *Signiﬁcance against control;
#Signiﬁcance against
respective Aldo dose without Epl; *
,#P ≤ 0.05, **
,##P ≤ 0.01, ***
,###P ≤ 0.005. n ¼ 3–8 per group.
Aldosterone impairs EPC function and vascularization 1279online, Figure S4A). Importantly, this treatment did not prevent the
aldosterone-mediated impairment on monocytic EPC function (see
Supplementary material online, Figure S4B), demonstrating that the
effects are independent from blood-pressure alterations.
We then evaluated the consequences of hyperaldosteronism on
endothelial function. Compared with controls, aldosterone-infused
mice demonstrated a signiﬁcant impairment of endothelium-
dependent vasodilatation, whereas treatment with eplerenone alle-
viated this effect (Figure 5A). There were also minor effects on
endothelium-independent vasodilatation suggesting lower sensi-
tivity to nitric oxide of aldosterone-infused mice without changes
in the maximal response to DEA-NONOate.
In addition to effects of aldosterone on large vessels, we deter-
mined alterations in the capacity for vascularization in two further
models. Aldosterone infusion markedly reduced endogenous vas-
cularization of implanted matrigel plugs (see Figure 4F) based on
measurements of the number of invading capillaries and total hae-
moglobin content (Figure 5B). Next, sprouting capacity of
explanted aortae was signiﬁcantly impaired after aldosterone infu-
sion independent from blood-pressure alterations (Figure 5C and
see Supplementary material online, Figure S4C). Importantly,
co-treatment with eplerenone normalized vascularization capacity
in both models of vascularization (Figure 5B and C).
Endothelial progenitor cell and
endothelial dysfunction in patients with
primary hyperaldosteronism:
improvement by mineralocorticoid
receptor blockade
To determine the clinical impact of the detrimental effects of
aldosterone seen in vitro and in mice experiments, we conducted
a clinical trial in patients with PHA. For comparison we recruited
controls of the same age with normal aldosterone plasma levels.
Beside a higher rate of antihypertensive medications there was
no difference in drug treatment, coronary artery disease, or dia-
betes in PHA patients compared with controls (Table 1). Patients
with established PHA had signiﬁcantly increased aldosterone
levels and aldosterone/renin ratios (Figure 6A). There was no
statistical signiﬁcant difference between the number of circulating
EPCs (CD34
+/KDR
+ cells) in PHA patients when compared
with controls (21.9+6.1 CD34
+/KDR
+/100 000 cells vs. 24.9+
8.9 CD34
+/KDR
+/100 000 cells; P ¼ 0.81). However, monocytic
(early) EPCs from patients with PHA showed an impaired
migratory potential compared with controls (Figure 6B). Treatment
of PHA patients with the MR blocker spironolactone for 4–6
weeks signiﬁcantly improved EPC function (Figure 6C).
Figure 3 Protein kinase-dependent effects of aldosterone on superoxide production in endothelial progenitor cells (EPCs). (A) Fluorescence-
microscopic detection of oxidated dihydroethidium (DHE) in human monocytic (early) EPC treated with aldosterone or vehicle control after
transfection with siRNA against NR3C2 or a scrambled control. (B) Measurement of oxidative stress (oxidated DHE) in EPCs co-treated with
aldosterone and a protein kinase A inhibitor (H-89, 24 h), a protein kinase C inhibitor (chelerythrine, 24 h) or eplerenone (Epl, 10 mM, 24 h).
(C) Monocytic EPC migratory capacity after aldosterone treatment with and without inhibition of PKA or PKC. Data are mean and SEM.
*Signiﬁcance against control;
#signiﬁcance against respective Aldo dose without Epl; *
,#P ≤ 0.05, ***
,###P ≤ 0.005. n ¼ 3–8 per group.
T. Thum et al. 1280Figure 4 Effects of aldosterone treatment in vivo on intracellular oxidative stress and function of endothelial progenitor cells (EPCs). (A)
Scheme of in vivo experiments: aldosterone or vehicle was delivered by implanted osmotic minipumps continuously for 2 weeks at a dose
rate of 50 mg/kg/day. After 7 days matrigel plugs were implanted. After 14 days EPC function and number were determined, as well as vascular-
ization of the implanted matrigel plug and sprouting capacity of explanted aortic rings. (B) Systolic and diastolic blood pressure of mice after 14
days of aldosterone- or vehicle infusion with and without concomitant oral treatment with the mineralocorticoid receptor-antagonist epler-
enone (Epl, 100 mg/kg of body weight). Effects of aldosterone treatment and mineralocorticoid receptor antagonism in vivo on oxidative
stress (oxidated dihydroethidium) in monocytic (early) EPCs (C), EPC differentiation (D) and EPC migratory capacity (E). (F) Number of
Dil-acLDL-labelled monocytic (early) EPCs in implanted matrigel plugs after infusion of 1 × 10
6 mineralocorticoid receptor-positive or
-negative EPCs to hyperaldosteronemic or control mice. (G) Integration (white arrow) or adhesion (gray arrow) of infused EPCs into
CD31-positive vascular structures in explanted matrigel plugs. Data are mean and SEM.; *Signiﬁcance against control;
#signiﬁcance against
respective Aldo dose without Epl; *
,#P ≤ 0.05, **
,##P≤0.01, ***
,###P≤0.005. n ¼ 4–6 individual experiments or animals per group.
Aldosterone impairs EPC function and vascularization 1281Primary hyperaldosteronism (PHA) patients additionally dis-
played signs of endothelial dysfunction, such as reduced reactive
hyperaemia index and increased arterial stiffness based on PAT
analysis (Figure 6D–F). Pharmacological MR blockade of PHA
patients did not signiﬁcantly alter reactive hyperaemia index but
normalized increased arterial stiffness thus indicating improvement
of endothelial biology (Figure 6G and H).
Discussion
The current study identiﬁed aldosterone to induce oxidative stress
and dysfunction of EPCs in a PKA-dependent manner. Mice infused
with aldosterone and patients with PHA displayed EPC functional
impairment, vascularization defects, and endothelial dysfunction.
Pharmacological inhibition or genetic ablation of the MR but not
blood pressure normalization by beta-blocker treatment pre-
vented EPC dysfunction in mice and patients with PHA.
Endothelial progenitor cells emerged as a surrogate biologic
marker for vascular function and cumulative cardiovascular
risk.
5,9,10 Mechanistically, various types of EPC contribute to neovas-
cularization and overall endothelial homeostasis. Indeed, neoangio-
genesis is signiﬁcantly suppressed when transplanted EPC are
depleted by activation of an inducible suicide gene,
44 whereas high
numbers of circulating EPC seem to protect cardiovascular diseased
patients from future cardiovascular events.
9 However, next to EPC
number, their functional capacity may be of additional and even
greater importance for the biological outcome. For instance, selec-
tive impairment of progenitor cell function contributes to an
Figure 5 Effects of aldosterone-infusion and mineralocorticoid receptor antagonism on endothelial function and vascularization capacity in
vivo.( A) Endothelium-dependent relaxation induced by acetylcholine (left) and endothelium-independent relaxation induced by
2-(N,N-diethylamino)-diazenolate-2-oxide (right) function measured in aortic ring preparations from mice treated with aldosterone (aldo)
or control and/or concomitant eplerenone (Epl) treatment (see Scheme Figure 4A). (B) Left CD31 staining of invading capillaries in matrigel
plugs explanted 2 weeks after continuous aldosterone- or placebo infusion to mice. (right) Statistical summary of the amount of invading capil-
laries into matrigel plugs per section (upper) and haemoglobin content of matrigel plugs as a further marker of vascularization (bottom). (C)
Number of sproutings from aortic ring preparations explanted from mice treated for 2 weeks with aldosterone or placebo and/or mineralo-
corticoid receptor antagonism. Data are mean and SEM. *Signiﬁcance against control;
#signiﬁcance against respective Aldo dose without Epl;
*
,#P ≤ 0.05, **
,##P≤0.01. n ¼ 5–6 individual experiments or animals per group.
T. Thum et al. 1282unfavourable left ventricular (LV) remodelling process
45 and fosters
vascular remodelling due to chronic impairment of endothelial
maintenance.
46 A previous study did not ﬁnd differences of EPC
proliferation and cell-cycle changes in patients with PHA.
47
However, other functional end points were not investigated and
control subjects had about three-fold higher plasma aldosterone
levels than the controls in our study. Here, we did not identify
changes of circulating EPC number in an animal model of hyperal-
dosteronism or in a clinical trial with patients suffering from PHA
compared with controls of the same age. In strong contrast, high
aldosterone levels severely impaired multiple functions of EPC
such as differentiation, proliferation, migration, and subsequently
vascularization capacity. Thus, aldosterone selectively led to qualitat-
ive rather than quantitative impairment of circulating EPC.
Figure 6 Endothelial progenitor cells (EPCs) and endothelial function in patients with primary hyperaldosteronism (PHA) and controls. (A)
Aldosterone plasma levels (left) and aldosterone/renin ratio (right) in patients with PHA and controls. Migratory capacity of monocytic (early)
EPCs isolated from controls and patients with PHA (B) before and after pharmacologic mineralocorticoid receptor (MR) antagonism (C).
Determination of endothelial function by reactive hyperaemia ratio (D, E) and the augmentation index (F) by a peripheral arterial tonometry
method based on a plethysmographic device (EndoPAT2000) in patients with PHA and controls. For patient characterization and n-values see
Table 1. Note, that only a subgroup of ﬁve to six patients with primary hyperaldosteronism was treated with spironolactone (C, G, H). Effects of
MR blockade with spironolactone on the reactive hyperaemia (G) and augmentation index (H) in patients with PHA. Data are mean and SEM.
*P ≤ 0.05, ***P ≤ 0.005.
Aldosterone impairs EPC function and vascularization 1283Endothelial progenitor cells express a variety of receptors,
which makes them responsive to changes of many growth
factors and hormones, such as oestrogen
3 or insulin-like growth
factor-1.
11 Here we show that various subtypes of EPC express
a functional MR that translocated to the nucleus upon aldoster-
one challenge leading to production of oxidative stress. Increased
intracellular ROS results in EPC dysfunction and impaired neovas-
cularization capacity.
6,12 This explains at least in part the func-
tional impairment of monocytic (early) EPC in conditions with
high aldosterone concentrations. We show that pharmacologic
blockade and genetic ablation of the MR in EPCs prevents
aldosterone-mediated oxidative stress end cellular dysfunction.
Mechanistically, aldosterone inhibits the formation of bone
marrow-derived progenitor cells by attenuating VEGFR-2, but
effects on circulating EPCs were not investigated.
48 Aldosterone
also impairs vascular reactivity by decreasing glucose-6-phosphate
dehydrogenase (G6PD) expression and activity in mature endo-
thelial cells.
18 We did not ﬁnd changes in G6PD expression in
monocytic EPCs by aldosterone treatment, suggesting that this
mechanism is not involved in aldosterone-mediated EPC dysfunc-
tion (data not shown). Protein kinase C has been described to be
involved in vascular oxidative stress.
49 We found that in EPCs
aldosterone-induced oxidative stress by PKA rather than
PKC-dependent mechanisms, which is line with ﬁndings that
PKA inhibition reduces ischaemia/reperfusion injury of myocardial
tissue.
50 The PKA inhibitor H-89 prevented both aldosterone-
mediated ROS formation as well as EPC functional defects. Inter-
estingly, paracrine activity appeared unaffected by aldosterone
challenge.
Impairment of EPC function was also observed in mice infused
with aldosterone for 14 days, which resulted in an overall
reduced vascularization capacity in different models, e.g. shown
by impaired endothelial invasion of implanted matrigel plugs and
attenuated endothelial cell sprouting capacity from vascular seg-
ments. The inhibitory effects of aldosterone on monocytic
(early) EPC function and vascularization capacity were indepen-
dent of the increase in blood pressure, as treatment with beta-
blocker normalized blood pressure but did not rescue the
aldosterone-mediated pathological effects. Our ﬁndings ﬁt well
with a report that aldosterone infusion exerts a detrimental vascu-
lar inﬂammatory phenotype with destruction of endothelial cells in
myocardial tissue.
51 However, it should be noted that under
certain conditions such as oxygen-induced retinopathy aldosterone
may also exert proangiogenic effects and stimulates pathological
angiogenesis in the retina.
52 We show that pharmacological block-
ade of the MR normalized attenuated vascularization capacity in a
mouse model of hyperaldosteronism. Moreover, genetic knock-
down of the MR prevented aldosterone-mediated impaired
homing of monocytic EPC to vascular structures in an in vivo matri-
gel plug assay. Our ﬁndings thus provide at least in part an expla-
nation for the ﬁndings that MR blockade improves
neovascularization and cardiac function after experimental myocar-
dial infarction
38 and leads to an improved clinical outcome in
patients with cardiac ischaemia and/or heart failure.
29,30,53,54
The observations of the present study are also of clinical impor-
tance for patients with PHA, which suffer from higher indices of
cardiovascular damage and face an increased risk of cardiovascular
events than controls of the same age, sex, and blood pressure
status.
25,55 Those patients display an increased media-to-lumen
ratio and administration of MR antagonists is associated with ame-
lioration of vascular remodelling.
27,56 We selected well-
characterized patients with PHA for functional analysis of EPC
and endothelial function, although patients with secondary hyper-
aldosteronism, e.g. after myocardial infarction or heart failure are
more common. However, the latter groups and the underlying
causes of hyperaldosteronism are rather heterogeneous and there-
fore those patients were not within the scope of the present inves-
tigation. We observed impaired cellular function of circulating
monocytic (early) EPC and endothelial dysfunction in patients
with PHA. Treatment with MR antagonists improved EPC and nor-
malized increased vascular stiffness, a major factor determining
increased systolic blood pressure and an independent marker of
cardiovascular risk.
57 Long-term effects of MR blockade (selective
vs. unselective MR blockers) on EPC biology and endothelial func-
tion in patients with PHA remain to be investigated.
The current study identiﬁes aldosterone as an important nega-
tive regulator of EPC function. Correction of aldosterone-
mediated impairment in EPC function by MR blockade may
favour endothelial regeneration at sites of tissue damage and
thus vascular homeostasis and endothelial function. Further pro-
spective studies are needed that determine the effects of MR
blockers as a novel therapeutic strategy against vascular disorders
with impaired function of EPC.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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